Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy ... against the AAV vector that interfere with ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for ... carried by an adeno-associated virus (AAV) vector, which is administered into ...

Dr. Scott Loiler The National MPS Society is pleased to announce the appointment of Dr. Scott Loiler as its new Chief Scientific Officer (C ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

serious adverse event in an AAV gene therapy clinical trial (INFINITY, company sponsor Adverum), this time the loss of sight in a patient with diabetic macular edema who was treated with a high dose ...

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.